These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 26506478

  • 1. Comparison of First- and Second-Generation Drug-Eluting Stents in an All-Comer Population of Patients with Diabetes Mellitus (from Katowice-Zabrze Registry).
    Kawecki D, Morawiec B, Dola J, Wańha W, Smolka G, Pluta A, Marcinkiewicz K, Ochała A, Nowalany-Kozielska E, Wojakowski W.
    Med Sci Monit; 2015 Oct 27; 21():3261-9. PubMed ID: 26506478
    [Abstract] [Full Text] [Related]

  • 2. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A.
    Clin Res Cardiol; 2016 Jul 27; 105(7):575-84. PubMed ID: 26689707
    [Abstract] [Full Text] [Related]

  • 3. First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry).
    Kawecki D, Morawiec B, Dola J, Wanha W, Smolka G, Pluta A, Marcinkiewicz K, Ochała A, Nowalany-Kozielska E, Wojakowski W.
    Arq Bras Cardiol; 2016 May 27; 106(5):373-81. PubMed ID: 27058257
    [Abstract] [Full Text] [Related]

  • 4. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 27; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 5. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
    Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R.
    JAMA Cardiol; 2017 Aug 01; 2(8):855-862. PubMed ID: 28658478
    [Abstract] [Full Text] [Related]

  • 6. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH, Brouwer J, Velders MA, van't Hof AW, Smits PC, Queré M, de Vries CJ, van Boven AJ.
    J Am Coll Cardiol; 2012 Jul 31; 60(5):381-7. PubMed ID: 22835668
    [Abstract] [Full Text] [Related]

  • 7. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2014 Jan 31; 7(1):55-63. PubMed ID: 24332419
    [Abstract] [Full Text] [Related]

  • 8. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G, Sauro R, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Palmieri V, Serino V, Rosato G, Suryapranata H, Di Lorenzo E.
    Diab Vasc Dis Res; 2015 Sep 31; 12(5):306-14. PubMed ID: 26150193
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW.
    Int J Cardiol; 2013 Dec 05; 170(1):36-42. PubMed ID: 24196314
    [Abstract] [Full Text] [Related]

  • 10. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L.
    JACC Cardiovasc Interv; 2013 May 05; 6(5):504-12. PubMed ID: 23602459
    [Abstract] [Full Text] [Related]

  • 11. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 05; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 12. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.
    J Interv Cardiol; 2013 Apr 05; 26(2):153-62. PubMed ID: 23363439
    [Abstract] [Full Text] [Related]

  • 13. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW.
    JACC Cardiovasc Interv; 2011 Nov 05; 4(11):1209-15. PubMed ID: 22115661
    [Abstract] [Full Text] [Related]

  • 14. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y, Colleran R, Kufner S, Giacoppo D, Rheude T, Michel J, Cassese S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators.
    Cardiovasc Diabetol; 2016 Sep 01; 15(1):124. PubMed ID: 27586678
    [Abstract] [Full Text] [Related]

  • 15. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC, Kok MM, Lam MK, Danse PW, Schramm AR, Jessurun GA, Tjon Joe Gin RM, van Houwelingen KG, Hautvast RW, Linssen GC, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, von Birgelen C.
    Clin Res Cardiol; 2016 Mar 01; 105(3):206-15. PubMed ID: 26329584
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.
    Catheter Cardiovasc Interv; 2013 Apr 01; 81(5):759-65. PubMed ID: 22488756
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease.
    Machado C, Raposo L, Dores H, Leal S, Campante Teles R, de Araújo Gonçalves P, Mesquita Gabriel H, Almeida M, Mendes M.
    Coron Artery Dis; 2014 May 01; 25(3):208-14. PubMed ID: 24419038
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.